Observational studyFrontiers in immunology2026
Dermographism in chronic spontaneous urticaria: associations with disease activity, autoimmunity, and disease duration.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: Dermographism is a frequent clinical finding in patients with chronic spontaneous urticaria (CSU) and may reflect enhanced mast-cell reactivity, increased disease severity, and prolonged disease persistence. This study aimed to evaluate the clinical significance of dermographism in CSU, including its relationship with disease activity, disease duration, response to H1-antihistamines, autoimmune status, and autologous serum skin test (ASST) positivity. Methods: A prospective observational study was conducted at the Dermatology Department, General Hospital "8th September", Skopje, North Macedonia, between December 2021 and November 2022, including 230 patients with CSU. Disease activity was assessed using the Urticaria Activity Score over 7 days (UAS7). Dermographism was clinically evaluated during dermatological examination using standardized mechanical provocation testing. Autoimmune status was determined by the presence of autoimmune disease and/or positivity for autoantibodies including anti-thyroid peroxidase antibodies (anti-TPO), antinuclear antibodies (ANA), and rheumatoid factor (RF). ASST was performed to assess autoreactivity. Results: Among 230 patients with chronic spontaneous urticaria (CSU), dermographism was present in 161 (70.0%). Patients with dermographism had significantly higher disease activity, being more frequently classified as severe according to UAS7 compared with those without dermographism (82.0% vs. 18.0%, χ²=14.4, p=0.00015). Dermographism was not associated with therapeutic response to H1-antihistamines (69.3% vs. 30.7%, χ²=0.12, p=0.73), autoimmune status (72.4% vs. 27.6%, χ²=1.1, p=0.29), or ASST positivity (72.9% vs. 27.1%, χ²=1.4, p=0.24). Patients with dermographism had a significantly longer disease duration than those without dermographism (58.5 ± 47.1 months; median 54 [IQR 15-91] months, Z = 2.3, p=0.022). Conclusions: Dermographism is a common finding in patients with chronic spontaneous urticaria and is associated with greater disease activity and longer disease duration, suggesting a more severe and persistent disease phenotype. Despite the observed trends, no significant associations were identified between dermographism and H1-antihistamine response. In addition, the lack of significant associations with autoimmune status and ASST positivity does not support a definitive relationship between dermographism and immune dysregulation. Routine assessment of dermographism may help identify CSU patients at risk for increased disease burden and prolonged disease course.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.